|
Dermatologic: Apparent hypersensitivity reactions (manifested by urticaria, pruritus, or rash, with or with-out fever), photosensitivity, purpura, oncholysis, pemphigus, pemphigoid, erythema multiforme, toxic epider-mal necrolysis, and Stevens-Johnson syndrome. Neurologic and Psychiatric: Text Continues Below
Anxiety, amnesia, convulsions, depression, hearing loss, insomnia, nervous-ness, neuralgia, neuropathy, paresthesia, somnolence, tinnitus, tremor, vertigo, and vision disturbances. Miscellaneous: As with other ACE inhibitors, a symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/ arthritis, myalgia, fever, vasculitis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Additionally, as with other ACE inhibitors, eosinophilic pneumonitis has been reported. Fetal/ Neonatal Morbidity and Mortality. See WARNINGS: Fetal/ Neonatal Morbidity and Mortality. Other: arthralgia, arthritis, dyspnea, edema, epistaxis, hypoglycemia (see PRECAUTIONS, Drug Interactions), impotence, increased sweating, malaise, myalgia, and weight gain. Clinical Laboratory Test Findings: Creatinine and Blood Urea Nitrogen: Increases in creatinine levels occurred in 1.2% of patients receiving ALTACE alone, and in 1.5% of patients receiving ALTACE and a diuretic. Increases in blood urea nitrogen lev-els occurred in 0.5% of patients receiving ALTACE alone and in 3% of patients receiving ALTACE with a diuret-ic. None of these increases required discontinuation of treatment. Increases in these laboratory values are more likely to occur in patients with renal insufficiency or those pretreated with a diuretic and, based on expe-rience with other ACE inhibitors, would be expected to be especially likely in patients with renal artery steno-sis. (See WARNINGS and PRECAUTIONS.) Page: << Prev | 1 | 2 | 3 | 4 | Next >>
|
.gif)
